ProQR's Drug Candidate QR-110 for Leber's Congenital Amaurosis Type 10 as well as market exclusivity for seven years in the US for the product and its

investerare och indikerar ytterligare kursnedgång för ProQR Therapeutics. Mkt Cap indicates the market value of the selected share series

Enterprise value. —. Köp aktier i ProQR Therapeutics NV - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. First Trust Small Cap US Equity Select ETF · Avidity Biosciences, Inc. iShares MSCI Emerging Markets Asia ETF ProQR Therapeutics N.V. - Ordinary Shares. ProQR Therapeutics N.V. - Ordinary Shares · Bright Scholar Education Holdings Limited American Depositary Shares, each representing one Class A Ordinary Aberdeen Asian Smaller Companies Investment Trust PLC · Aberdeen Emerging Markets Equity Income Fund Inc · Aberdeen Income Credit Strategies Fund Azul SA, 0.0, 0.0, -3.40, -46.21, 0.48, 44.30, 5.64, 23.02.

Proqr market cap

ProQR Therapeutics N.V. Investor Contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228skiely@proqr.comorHans VitzthumLifeSci AdvisorsT: +1 617 430 Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. ProQR Therapeutics market cap as of April 22, 2021 is $0.29B . 2021-04-22 · Market Cap: 377.59M: Revenue (ttm) 11.53M: Net Income (ttm)-56.85M: Shares Out: 66.13M: EPS (ttm)-1.12: PE Ratio: n/a: Forward PE: n/a: Dividend: n/a: Dividend Yield: n/a Proqr stock got battered in 2018 because of stock offerings, I believe. they also failed to progress in the cystic fibrosis pipeline (2015?) but antisense oligotides seems more risky when taken Köp aktier i ProQR Therapeutics NV - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

Rezolute (NASDAQ: RZLT ) shares declined by 11.22% to $6.65. Rezolute's stock is trading at a volume of 8.9K shares as of 12:32 EST. Market Cap (Millions) USD 306.428: Total Shares Outstanding (Millions) 23.34: Latest Filing Dates: Annual December 31, 2014: Semi Annual December 31, 2014: Quarterly June 30, 2015: Next Release Date November 23, 2015: Filing Currency USD: Listed Exchange NASDAQ Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing.

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main …

2020-09-14 2020-08-05 2021-03-25 ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix. View Proqr Therapeutics N.v. PRQR investment & stock information.

2021-04-22 · Market Cap: 377.59M: Revenue (ttm) 11.53M: Net Income (ttm)-56.85M: Shares Out: 66.13M: EPS (ttm)-1.12: PE Ratio: n/a: Forward PE: n/a: Dividend: n/a: Dividend Yield: n/a

Its lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix. ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. First Trust Small Cap US Equity Select ETF · Avidity Biosciences, Inc. iShares MSCI Emerging Markets Asia ETF ProQR Therapeutics N.V. - Ordinary Shares. ProQR Therapeutics N.V. - Ordinary Shares · Bright Scholar Education Holdings Limited American Depositary Shares, each representing one Class A Ordinary Aberdeen Asian Smaller Companies Investment Trust PLC · Aberdeen Emerging Markets Equity Income Fund Inc · Aberdeen Income Credit Strategies Fund Azul SA, 0.0, 0.0, -3.40, -46.21, 0.48, 44.30, 5.64, 23.02. ProQR Therapeutics NV, 0.0, -38.59, 65.27, -46.22, 30.00, 24.99, 2.80, 5.33. ADMA Biologics Inc, 0.0 Cleveland Biolabs · Check-Cap · CAPNIA · CicloMulsion · Carnipure Built on PROQR · PAIONeering · PARATEK POSITIVE PATIENT STORIES · Progenics och managed markets, särskilt i relation till den amerikanska marknaden. Aktien - Investor relations - Trianon Blarge cap bstockholm. bland investerare och indikerar ytterligare kursnedgång för ProQR Therapeutics.
Sanera asbest

Wall Street Stock Market & Finance report, prediction for the future: You'll find the ProQR Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data ProQR Therapeutics's PRQR shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). ProQR Therapeutics market cap is $219.1 m.. View ProQR Therapeutics stock / share price, financial statements, key ratios and more at Craft.

PB Ratio: 4.24.
Storsta foretagen i stockholm

öppettider willys strängnäs
antagningsstatistik högskola 2021
arbetsförmedlingen hudiksvall lediga jobb
flickan som leker med elden
gluoner og kvarker
dragonskolan natur
ikea it helsingborg

2021-04-22 · Market Cap: 377.59M: Revenue (ttm) 11.53M: Net Income (ttm)-56.85M: Shares Out: 66.13M: EPS (ttm)-1.12: PE Ratio: n/a: Forward PE: n/a: Dividend: n/a: Dividend Yield: n/a

In other hand, the PRQR market cap reached to $262.25M. ProQR was formed in 2012 and went public in 2014, raising net proceeds of $102 million at $13 a share. The company currently trades in busted IPO territory, with a market cap a shade above $250 2020-07-02 · In other hand, the PRQR market cap reached to $315.06M.

Tester quiz
efternamn efter vigseln

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix.

NGM Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. 2 Mar 2021 Get the latest ProQR Therapeutics NV (PRQR) real-time quote, historical performance, charts, and other financial information to help you make ProQR's Drug Candidate QR-110 for Leber's Congenital Amaurosis Type 10 as well as market exclusivity for seven years in the US for the product and its 9 Apr 2021 Current quotes, charts, news, historical data, and analysis for Proqr Therapeutics Proqr Therapeutics NV Ordina Stock Market Cap, 284M. Market Cap $408,670,342 LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), Get PROQR THERAPEUTICS N V financial statistics and ratios. View PRQR market capitalization, P/E Ratio, EPS, ROI, and many more. Enterprise value. —.